The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform. Novo Nordisk gets a license to three preclinical-stage cardiovascular disease programmes from Valo Health...

  Sandoz, a global leader in generic and biosimilar medicines, announced that it has entered into a development and commercialization agreement with Samsung Bioepis. The agreement provides Sandoz with the exclusive rights to commercialize the biosimilar SB17 ustekinumab in the...

  Sandoz, a global leader in generic and biosimilar medicines, announced that the European Commission (EC) granted marketing authorization for the first and only biosimilar Tyruko® (natalizumab), developed by Polpharma Biologics. The European approval for Tyruko comes a month...

  Italian company Alfasigma has signed a definitive agreement for the acquisition of all issued and outstanding shares in Intercept Pharmaceuticals. Alfasigma will pay $19 for each share of Intercept. The acquisition will help boost Alfasigma’s gastroenterology and hepatology...

  Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Mindset Pharma, Inc. (Mindset) announce that they have entered into a definitive arrangement agreement pursuant to which Otsuka will acquire Mindset for approximately CAD 80 million in an all-cash transaction. The Otsuka and Mindset...

  Global science and technology provider Danaher has signed a definitive agreement for the acquisition of all outstanding stakes in UK-based protein consumables supplier Abcam in a deal valued at $5.7bn. Under the terms of the agreement, Danaher will acquire all the outstanding...

    Scientific instruments maker Bruker has agreed to buy PhenomeX for about $108 million, marking its entry into the market for functional single-cell biology research systems. PhenomeX supplies an analysis platform that enables researchers to characterize tens of...

  Revolution Medicines, Inc.  a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. today announced a definitive agreement through which Revolution Medicines plans to acquire EQRx in an all-stock transaction intended to add more...

  BioNTech has officially completed the acquisition of InstaDeep Ltd.—a technology company in the artificial intelligence (AI) and machine learning (ML) space— for approximately $549 million.  The takeover follows a collaboration between the two parties since 2019 and an equity...

Biogen agreed to give $172.50 per share in cash to Reata, accompanied by term debt issuance. The transaction will close in the fourth quarter of 2023. Biogen’s president and chief executive officer, Christopher Viehbacher, said the company believes it has the foundation in place to...